Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).

Lijuan ZengJamie PerinAlden L GrossDavid ShadeKrista L LanctôtAlan J LernerJacobo E MintzerOlga Brawman-MintzerPrasad R PadalaChristopher H van DyckAnton P PorsteinssonSuzanne CraftAllan LeveyNathan HerrmannPaul B Rosenberg

Published in: International journal of geriatric psychiatry (2024)

MPH use in AD patients for treating apathy is relatively safe, particularly notable given the many medical comorbidities in this population. There was a statistically significant but modest weight loss associated with MPH use, and clinicians are thus advised to monitor weight during MPH treatment.

Keyphrases

weight loss
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
body mass index
attention deficit hyperactivity disorder
physical activity
prognostic factors
study protocol
cognitive decline
phase iii
gastric bypass
mild cognitive impairment